Small cell lung cancer (sclc) Trials in New York, United States
Conditions / Small cell lung cancer (sclc) / New York, United States
Research into Small cell lung cancer (sclc) spans multiple therapeutic approaches and trial phases.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | RECRUITING | PHASE1/PHASE2 |
| NCT04180176 | Prospective Clinicogenomic Program | COMPLETED | PHASE4 |
| NCT07488923 | A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) | NOT_YET_RECRUITING | — |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | COMPLETED | PHASE1 |
| NCT02934503 | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) | TERMINATED | PHASE2 |
| NCT06736418 | Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy | ACTIVE_NOT_RECRUITING | — |
| NCT05740566 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06885424 | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products | ENROLLING_BY_INVITATION | — |
| NCT03066778 | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | COMPLETED | PHASE3 |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | RECRUITING | PHASE1/PHASE2 |